Neutrophil infiltration and oxidative stress may play a critical role in methotrexate-induced renal damage

Chemotherapy

Volumn 55, Issue 2, 2009, Pages 83-90

  Kolli, Viswa Kalyan ^a   Abraham, Premila ^a   Isaac, Bina ^a   Selvakumar, Dhayakani ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Methotrexate; Myeloperoxidase; Neutrophil infiltration; Oxidative stress; Renal damage

Indexed keywords

CARBONYL DERIVATIVE; CATALASE; CREATININE; GLUTATHIONE PEROXIDASE; GLUTATHIONE TRANSFERASE; LIPID; MALONALDEHYDE; METHOTREXATE; MYELOPEROXIDASE; SUPEROXIDE DISMUTASE; THIOL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; GLOMERULUS; KIDNEY; KIDNEY HOMOGENATE; KIDNEY INJURY; KIDNEY TUBULE; MALE; MICROSCOPY; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; KIDNEY; MALE; METHOTREXATE; NEUTROPHIL INFILTRATION; OXIDATIVE STRESS; PEROXIDASE; RATS; RATS, WISTAR; SUPEROXIDE DISMUTASE;

EID: 58149471362     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000192391     Document Type: Article

References (65)

1. Djerassi I: High-dose methotrexate (NSC-740) and citrovorum factor (NSC-3590) rescue: background and rationale. Cancer Chemother Rep 1975;6:3-6.
2. Ackland SP, Schilsky RL: High-dose methotrexate: a critical reappraisal. J Clin Oncol 1987;5:2017-2031.
3. Frei E 3rd, Blum RH, Pitman SW, et al: High dose methotrexate with leucovorin rescue: rationale and spectrum of antitumor activity. Am J Med 1980;68:370-376.
4. Djerassi I: Methotrexate infusions and intensive supportive care in the management of children with acute lymphocytic leukemia: follow-up report. Cancer Res 1967;27:2561-2564.
5. Yap HY, Blumenschein GR, Yap BS, et al: High-dose methotrexate for advanced breast cancer. Cancer Treat Rep 1979;63:757-761.
6. Allegra CJ: Antifolates; in Chabner BA, Collins JM (eds): Cancer Chemotherapy. Philadelphia, Lippincott, 1990, pp 110-153.
7. Jolivet J, Cowan KH, Curt GA, et al: The pharmacology and clinical use of methotrexate. N Engl J Med 1983;309:1094-1104.
8. Albertioni F, Flato B, Seideman P, et al: Methotrexate in juvenile rheumatoid arthritis: evidence of age dependent pharmacokinetics. Eur J Clin Pharmacol 1995;47:507-511.
9. Bright RD: Methotrexate in the treatment of psoriasis. Cutis 1999;64:332-334.
10. Doan T, Massarotti E: Rheumatoid arthritis, an overview of new and emerging therapies. J Clin Pharmacol 2005;45:751-762.
11. Helen STE, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS: Hepatic effects of long term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000;5:3150-3156.
12. Izzedine H, Launay-Vacher V, Karie S, Caramella C, de Person F, Deray G: Is low-dose methotrexate nephrotoxic? Case report and review of the literature. Clin Nephrol 2005;64:315-319.
13. Nyhlén A, Johnsson A, Höglund P, Ljungberg B, Nilsson-Ehle I: Gastrointestinal damage induced by cytostatic treatment does not affect the bioavailability of co-trimoxazole. Chemotherapy 1999;45:399-340.
14. Vezmar S, Becker A, Bode U, Jaehde U: Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 2003;49:92-104.
15. Abelson HT, Fosburg MT, Beardsley GP, et al: Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol 1983;1:208-216.
16. Ahmad S, Shen FH, Bleyer WA: Methotrexate-induced renal failure and ineffectiveness of peritoneal dialysis. Arch Intern Med 1978;138:1146-1147.
17. Seideman P, Müller-Suur R, Ekman E: Renal effects of low dose methotrexate in rheumatoid arthritis. J Rheumatol 1993;20:1126-1128.
18. Grönroos M, Chen M, Jahnukainen T, Capitanio A, Aizman RI, Celsi G: Methotrexate induces cell swelling and necrosis in renal tubular cells. Pediatr Blood Cancer 2006;46:624-629.
19. Jacobs SA, Stoller RG, Chabner BA, et al:7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high dose methotrexate. J Clin Invest 1976;57:534-538.
20. Lankelma J, van der Klein E, Ramaekers F: The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy. Cancer Lett 1980;9:133-142.
21. Messmann R, Allegra C: Antifolates; in: Chabner B, Longo D (eds): Cancer Chemotherapy and Biotherapy. Philadelphia, Lippincott Williams & Wilkins, 2001, pp 139-184.
22. Jahovic N, Sener G, Cevik H, Ersoy Y, Arbak S: Amelioration of methotrexate induced enteritis by melatonin in rats. Cell Biochem Funct 2004;22:169-178.
23. Sener G, Eksioglu-Demiralp E, Cetiner M, Ercan F, Yegen BC: Glucan ameliorates methotrexate induced oxidative organ injury via its antioxidant and immunomodulatory effects. Eur J Pharmacol 2006;542:170-178.
24. Gao F, Horie T: A synthetic analog of prostaglandin E 1 prevents the production of reactive oxygen species in the intestinal mucosa of methotrexate-treated rats. Life Sci 2002;71:1091-1099.
25. Kolli VK, Abraham P, Isaac B: Alteration in antioxidant defense mechanisms in the small intestines of methotrexate treated rat may contribute to its gastrointestinal toxicity. Cancer Therapy 2008;6:17-26.
26. Jahovic N, Cevik H, Sehirli AO, Yeǧen BC, Sener G: Melatonin prevents methotrexate-induced hepatorenal oxidative injury in rats. J Pineal Res 2003;34:282-287.
27. Wallace JL, Macnaughton WK, Morris GP, Beck PL: Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 1989;96:29-36.
28. Diaz-Granados N, Howe K, Lu J, McKay DM: Dextransulfate sodium-induced colonic histopathology, but not altered epithelial ion transport, is reduced by inhibition of phosphodiesterase activity. Am J Pathol 2000;156:2169-2177.
29. Ohkawa H, Ohishi N, Yagi K: Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979;95:351-358.
30. Sohal RS, Agarwal S, Dubey A, Orr WC: Protein oxidative damage is associated with life expectancy of houseflies. Proc Natl Acad Sci USA 1993;90:7255-7259.
31. Ohkuma N, Matsuo S, Tutsui M, Ohkawara A: Superoxide dismutase in the epidermis. Nippon Hifuka Gakkai Zasshi 1982;92:583-590.
32. Aebi IH: Catalase in vitro. Methods Enzymol 1984;105:121-126.
33. Awasthi YC, Dao DD, Saneto RP: Interrelationship between anionic and cationic forms of glutathione S transferases of human liver. Biochem J 1980;191:1-10.
34. Racker E: Glutathione reductase from bakers' yeast and beef liver. J Biol Chem 1955;217:855-865.
35. Nakamura W, Hosada S: Purification and properties of rat liver glutathione peroxidase. Biochim Biophys Acta 1974;358:251-261.
36. Sedlak J, Lindsay RH: Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968;25:192-205.
37. Habeeb A: Reaction of protein sulfhydryl groups with Ellman's reagent. Methods Enzymol 1972;25:457.
38. Van Vleet TR, Schnellmann RG: Toxic nephropathy: environmental chemicals. Semin Nephrol 2003;23:500-508.
39. Therond P: Oxidative stress and damages to biomolecules (lipids, proteins, DNA). Ann Pharm Fr 2006;64:383-389.
40. Tariq M, Morais C, Sobki S, Al Sulaiman M, Al Khader A: Effect of lithium on cyclosporine induced nephrotoxicity in rats. Ren Fail 2000;22:545-560.
41. Peyrou M, Hanna PE, Cribb AE: Cisplatin, gentamicin, and p -aminophenol induce markers of endoplasmic reticulum stress in the rat kidneys. Toxicol Sci 2007;99:346-353.
42. Abraham P, Sugumar E: Enhanced PON1 activity in the kidneys of cyclophosphamide treated rats may play a protective role as an antioxidant against cyclophosphamide induced oxidative stress. Arch Toxicol 2008;82:237-238
43. Oktem F, Yilmaz HR, Ozguner F, Olgar S, Ayata A, Uzare E, Uz E: Methotrexate-induced renal oxidative stress in rats: the role of a novel antioxidant caffeic acid phenethyl ester. Toxicol Ind Health 2006;22:241-247.
44. Devrim E, Cetin R, Kiliçoglu B, Ergüder BI, Avci A, Durak I: Methotrexate causes oxidative stress in rat kidney tissues. Ren Fail 2005 ;27:771-773.
45. Uz E, Oktem F, Yilmaz HR, Uzar E, Ozgüner F: The activities of purine-catabolizing enzymes and the level of nitric oxide in rat kidneys subjected to methotrexate: protective effect of caffeic acid phenethyl ester. Mol Cell Biochem 2005;277:165-170.
46. Traber DL, Adams T Jr, Sziebert L, Stein M, Traber L: Potentiation of lung vascular response to endotoxin by superoxide dismutase. J Appl Physiol 1985;58:1005-1009.
47. Sener G, Ekşioǧlu-Demiralp E, Cetiner M, Ercan F, Sirvanci S, Gedik N, Yeǧen BC: L-Carnitine ameliorates methotrexate-induced oxidative organ injury and inhibits leukocyte death. Cell Biol Toxicol 2006;22:47-60.
48. Cetinkaya A, Kurutas EB, Bulbuloglu E, Kantarceken B: The effects of N-acetylcysteine on methotrexate-induced oxidative renal damage in rats. Nephrol Dial Transplant 2007;22:284-285.
49. Cetiner M, Sener G, Sehirli AO, Ekşioǧlu-Demiralp E, Ercan F, Sirvanci S, Gedik N, Akpulat S, Tecimer T, Yeǧen BC: Taurine protects against methotrexate-induced toxicity and inhibits leukocyte death. Toxicol Appl Pharmacol 2005;209:39-50.
50. Güngör N, Godschalk RWL, Pachen DM, Van Schooten FJ, Knaapen AM: Activated neutrophils inhibit nucleotide excision repair in human pulmonary epithelial cells: role of myeloperoxidase. FASEB J 2007;21:2359-2367.
51. Klebanoff SJ, Clark RA: The Neutrophil. Amsterdam, North-Holland Publishing Co., 1978.
52. Zimmerman BJ, Granger N: Reperfusion injury. Surg Clin North Am 1992;72:65-83.
53. Sekizuka E, Grisham MB, Li M: Inflammation induced intestinal hyperemia in the rat: role of neutrophils. Gastroenterology 1988;95:1528-1534.
54. Pattison DI, Davies MJ: Reactions of myeloperoxidase-derived oxidants with biological substrates: gaining chemical insight into human inflammatory diseases. Curr Med Chem 2006;13:3271-3290.
55. Winterbourn CC, Kettle AJ: Biomarkers of myeloperoxidase-derived hypochlorous acid. Free Radic Biol Med 2000;29:403-409.
56. Pattison DI, Davies MJ: Absolute rate constants for the reaction of hypochlorous acid with protein side chains and peptide bonds. Chem Res Toxicol 2001;14:1453-1464.
57. Buss IH, Darlow BA, Winterbourn CC: Elevated protein carbonyls and lipid peroxidation products correlating with myeloperoxidase in tracheal aspirates from premature infants. Pediatr Res 2000;47:640-645.
58. Den Hartog GJ, Vegt E, van der VijghW J, Haenen GR, Bast A: Hypochlorous acid is a potent inhibitor of acetylcholinesterase. Toxicol Appl Pharmacol 2002;181:228-232.
59. an Haaften RI, den Hartog GJ, Evelo CT, Haenen GR, Bast A: Hypochlorous acid is a potent inhibitor of GST P1-1. Chem Biol Interact 2001;138:77-83.
60. Dalle-Donne I, Aldini G, Carini M, Colombo R, Rossi R, Milzani A: Protein carbonylation, cellular dysfunction, and disease progression. J Cell Mol Med 2006;10:389-406.
61. Malle E, Furtmüller PG, Sattler W, Obinger C: Myeloperoxidase: a target for new drug development? Br J Pharmacol 2007;152:838-854.
62. Cho Y, Jang YY, Han ES, Lee CS: The inhibitory effect of ambroxol on hypochlorous acid induced tissue damage and respiratory burst of phagocytic cells. Eur J Pharmacol 1999;383:83-91.
63. Zhu BZ, Carr AC, Frei B: Pyrrolidine dithiocarbamate is a potent antioxidant against hypochlorous acid-induced protein damage. FEBS Lett 2002;532:80-84.
64. Carr AC, Tijerina T, Frei B: Vitamin C protects against and reverses specific hypochlorous acid- and chloramines dependent modifications of low-density lipoprotein. Biochem J 2000;346:491-499.
65. Galijasevic S, Abdulhamid I, Abu-Soud HM: Melatonin is a potent inhibitor for myeloperoxidase. Biochemistry 2008;47:2668-2677.